Publications & Research

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer’s Disease and Cognitively Normal Subjects

The objectives of this study were to examine the effective dose range and the test–retest reliability of florbetapir F 18 using, first, visual assessment by independent raters masked to clinical information and, second, semiautomated quantitative measures of cortical target area to cerebellum standardized uptake value ratios (SUVr) as primary outcome measures. Florbetapir F 18 appears to have a wide effective dose range and a high test–retest reliability for both quantitative (SUVr) values and visual assessment of the ligand. These imaging performance properties provide important technical information on the use of florbetapir F 18 and PET to detect cerebral amyloid aggregates.

Click here to access the full study.

  • Imaging Forward

    In just 20 years, medical imaging has dramatically improved health outcomes and lowered costs. Imagine what the future holds. Learn More

  • MITA Smart Initiative

    Promoting patient safety and enhancing the quality of medical imaging technology with MITA Smart Standards. Learn More

  • Fluoro Pharma

    Why I Joined MITA – FluoroPharma Medical, Inc.

    Hear from Thomas Tulip, Ph.D, President, FluoroPharma Medical, Inc. on why his organization joined MITA.

    Learn More